Biogen and Samsung Bioepis have laid to rest a long-running patent wrangle with AbbVie regarding a biosimilar form of the latter’s blockbuster Humira.

The parties have now come to an agreement over the commercialisation of Biogen and Samsung Bioepis’ Imraldi (biosimilar adalimumab), the specific terms of which are being kept under wraps.

It was disclosed, however, that under the settlement AbbVie will grant patent licenses for the use and sale of Imraldi in Europe, on a country-by-country basis, while Biogen and Samsung Bioepis will make royalty payments in return.

The companies have agreed to dismiss all pending patent litigation, paving the way for the drug’s launch in Europe, which is scheduled for October.

“Biogen already markets two biosimilars in Europe and the planned introduction of Imraldi on October 16 could potentially expand patient choice by offering physicians more options to meet the needs of patients while delivering significant savings to healthcare systems,” said Ian Henshaw, global head of Biosimilars at Biogen.

Humira, an anti-TNF monoclonal antibody, pulls in annual sales of nearly $15 billion across its range of indications for inflammatory diseases.